1 Characterization and comparison of immunity against MPXV for individuals infected

2 with MPXV or vaccinated with modified vaccinia Ankara vaccines

3

4 Authors

- 5 Aurélie Wiedemann^{1,2¥}, Mathieu Surénaud^{1,2¥}, Mathieu Hubert³, José-Luis Lopez Zaragoza⁴,
- 6 Alexandre Ribeiro^{1,2}, Cécile Rodrigues^{1,2}, Emile Foucat^{1,2}, Harouna Diombera^{1,4}, Corinne

7 Krief^{1,2}, Olivier Schwartz^{1,3}, Jean-Daniel Lelièvre^{1,2,4}, and Yves Lévy^{1,2,4*}

8 Affiliations

- 9 1. Vaccine Research Institute, Université Paris-Est Créteil, France
- 10 2. INSERM U955, Institut Mondor de Recherche Biomedicale (IMRB), Team Lévy,
- 11 Créteil, France
- Institut Pasteur, Université Paris Cité, Virus and Immunity Unit, CNRS UMR3569,
 75015 Paris, France
- Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier,
 Service Immunologie Clinique, Créteil, France
- 16
- 17 *Correspondence: Pr. Yves Lévy, Vaccine Research Institute, INSERM U955, Hopital Henri
- 18 Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, France, Phone: +33 (0) 1 49
- 19 81 44 42, Fax: +33 (0) 1 49 81 24 69, E-mail: <u>vves.levy@aphp.fr</u>
- 20 ^{*}these authors contributed equally

22 Abstract (250 words)

23 The 2022 monkeypox virus (MPXV) outbreak has revitalized questions about immunity against MPXV 24 and vaccinia-based vaccines (VAC-V), but studies are limited. We analyzed immunity against MPXV in 25 individuals infected with MPXV or vaccinated with the licensed modified vaccinia Ankara vaccine 26 (MVA)-BN or an experimental MVA-HIVB vaccine. The frequency of neutralizing antibody (NAb) 27 responders was higher among MPXV-infected individuals than MVA vaccinees. Both MVA vaccines 28 induced similar and strong humoral responses. Similarly, we show a higher frequency and magnitude 29 (5-fold) of T-cell responses, mainly mediated by CD8⁺ T cells, against a peptide pool containing 30 selected sequences from MPXV, Variola, and VAC-V in MPXV-infected individuals than MVA 31 vaccinees. We describe a hierarchy of cross-reactive T-cell responses against five peptide pools that 32 are highly homologous between VAC-V and MPXV 2022, with the highest frequency of responders 33 against MVA-121L and MVA-018L proteins. Both vaccines stimulated a notable frequency of 34 polyfunctional CD4⁺ and CD8⁺ T-cell responses, with a subset of CD4⁺ T cells showing a mixed 35 cytokine profile. Finally, we found that smallpox vaccination in childhood positively affected humoral 36 but not T-cell vaccine responses, whereas these responses were not affected in people living with 37 HIV. These findings contribute to deciphering and monitoring the profile of immunity to MPXV and 38 MVA. In the context of a potential threat of the reemergence of smallpox following bioterrorism, the 39 diversification and availability of potent vaccines is crucial. The comparable immunogenicity of both 40 MVA vaccines emphasizes the potential utility of MVA-HIVB as a valuable new tool for controlling 41 MPXV outbreaks.

42

43

45 Introduction

46 Mpox virus (MPXV, formerly known as monkeypox) is a zoonotic poxvirus disease that is usually 47 endemic to countries in West and Central Africa and caused by an Orthopoxvirus (OPXV). This viral 48 genus includes smallpox. The cessation of massive vaccination in 1980 after the eradication of 49 smallpox has increased the risk of the emergence of OPXV in humans. Since then, the number of 50 cases and geographic range have increased substantially, possibly related to the waning of smallpox vaccine-induced immunity. The recent outbreak in 2022 is linked to a genotypically distinct MPXV 51 52 related to West Africa. It was first detected in Europe and then spread throughout the world ¹. The 53 large number of cases in more than 110 countries represented a global threat. This prompted the 54 World Health Organization to claim a public health emergency of international concern.

The recent 2022 mpox outbreak was unusual, with an absence of direct links to endemic countries and sustained human-to-human transmission. Mpox causes an illness with a febrile rash in humans, similar to but milder than smallpox. Populations at risk were people living with HIV (PLWHIV), men who have sex with men (MSM), bisexuals, and young individuals without previous smallpox vaccination during childhood ^{2, 3, 4, 5}. The case fatality rate was low (0.1%) relative to previous outbreaks that occurred in West (lethality rate 1-6%) and Central Africa (11%), but infections were severe and the lethality rates were high among PLWHIV with advanced infection ⁴.

62 Three generations of vaccines based on vaccinia virus (VACV) were originally developed against smallpox ⁶. The first-generation vaccine is comprised of live VACV, (e.g., Dryvax) and was used for 63 64 the eradication of smallpox. ACAM2000 is a second-generation vaccine, also based on live VACV 65 (Emergent Product Development Gaithersburg, MD, USA). This vaccine offers an improved safety 66 profile and has been made accessible to healthcare workers and individuals aged 18 years or older. 67 During the recent outbreak, vaccination campaigns were based on a third generation of a safer 68 vaccine consisting of an attenuated modified vaccinia virus Ankara (MVA) and is incapable of replication in humans⁷. This vaccine, produced by Bavarian Nordic (MVA-BN, commercialized under 69 70 the names of IMVANEX or JYNNEOS), is the only vaccine approved for mpox prevention. Previous studies showed these second- and third-generation vaccines to be highly immunogenic ^{8, 9, 10, 11, 12}. 71 However, data demonstrating protection by IMVANEX has only been shown in animal models ^{7, 13, 14,} 72

^{15, 16}. Furthermore, this vaccine is available in only limited quantities ¹⁷, highlighting the need to develop
 other vaccine candidates to control the expansion of cases in an epidemic situation.

The recent report of new cases of MPXV reinfection in MVA-BN-vaccinated individuals ^{18, 19} is a true 75 concern and raises questions about the protective and durable immunity conferred by this attenuated 76 vaccine. Dryvac-induced B- and T-cell immunity can persist for years (> 50 years)^{20, 21, 22, 23, 24}. Recent 77 studies have shown low-level and rapid waning of neutralizing antibodies after MVA-BN 78 (IMVANEX/JYNNEOS) vaccination ^{25, 26}. MVA-BN does not elicit potent maturation of the B-cell 79 repertoire, a critical process for neutralization of the virus and durability of the response ²⁷, raising the 80 81 question of the respective roles of B-cell and cellular immunity in vaccine protection. Few studies have investigated T-cell responses against MPXV in humans ^{28, 29, 30}. Data concerning the quality of immune 82 responses to MPXV and the currently used third generation of MVA-based vaccines are limited ²⁷. 83

84 We recently examined the neutralizing antibody (NAb) responses to MVA and MPXV in convalescent 85 patients who had recovered from mpox infection, those who have received historic smallpox 86 vaccination, and those who had been administered MVA-based vaccines, including an experimental 87 MVA-HIVB vaccine ³¹. A comparison of B-cell responses showed large differences in NAb levels 88 between the various cohorts of individuals. High NAb titers were measured in ancient smallpox-89 vaccinated MPXV-infected patients, suggesting potential cross-protection mediated by hybrid 90 immunity. Here, we extended these data by characterization of the cellular immunity of individuals 91 infected with MPXV or receiving MVA-based vaccines. We describe the cross reactivity and the impact 92 of historical smallpox vaccination and HIV status of participants on these responses.

94 Results

95 Participants enrolled in the study

96 We analyzed peripheral blood mononuclear cells and sera from 61 individuals, including eight MPXV-97 infected individuals (21 days after symptoms onset and noted as being convalescent, Conv.) and 53 98 MVA-BN vaccine recipients. Individuals born after 1980, the data of cessation of smallpox vaccination, 99 received two doses of the vaccine, with an interval of 28 to 35 days, whereas older individuals (born 100 before 1980 and who received a smallpox vaccination during childhood) received a single dose 101 according to national recommendations. The median age of MPXV-infected and vaccinated individuals 102 was 33 [24-47] and 43 [32-56] years, respectively. All participants were male. Among them, 30/61 103 individuals were living with HIV (PLWHIV) (6/8 MPXV-infected and 24/53 vaccinated, all under 104 antiretroviral treatment and with a CD4 count > 200/mm³). The study also included ten healthy 105 volunteers (median age 24 [21-26], 70% male), who received two doses (separated by 8 weeks) of the 106 MVA-HIVB, candidate MVA vaccine carrying HIV epitopes in the setting of the ANRS VRI01 clinical trial 32. 107

108 Neutralizing antibodies induced by MPXV infection and MVA-BN and MVA-HIVB vaccination

109 We quantified the neutralizing activity of sera from MPXV-infected and MVA-vaccinated individuals. 110 We used two assays to measure neutralization titers against MVA-GFP and an authentic clinical 111 MPXV strain isolated from a typical lesion of a French patient infected in June 2022 grown on Vero E6 112 cells (GenBank accession number OQ249661), with or without complement supplementation, as recently reported by our group ³¹ (Figure 1). We detected anti-MVA NAbs in 50% of MPXV-infected 113 114 individuals (median ED50: 38.4). Ninety-five percent (median ED50 of 128.8) of individuals born 115 before 1980 and 13% (median ED50 of 15) born after were neutralizers after a single dose of MVA-116 BN, highlighting the importance of priming during childhood. The second dose of vaccine increased 117 the percentage of neutralizers among younger individuals to 72% (median ED50: 201). The addition of 118 complement increased NAb titers and the percentage of responders, with 100% neutralizers detected 119 among MPXV-infected (median ED50: 594.2) and older vaccinated individuals (median ED50: 445.9) 120 and 94% among the younger vaccinees (median ED50: 669.5) two weeks after full vaccination. We 121 further assessed the immunogenicity of MVA as a vaccine platform by measuring NAb levels in sera 122 from healthy donors, all born after 1980, who received two doses of the MVA-HIVB vaccine candidate 123 in the VRI01 trial. Two weeks after the second dose, 90% were responders, regardless of the

presence of complement (median ED50: 1465 and 460.3, with and without complement, respectively)(Figure 1A).

126 The NAb titers and frequency of responders were low in the absence of complement in the MPXV 127 assay ³¹. Among MPXV-infected individuals, 25% (2/8) and 88% (7/8) were responders in assays 128 without and with complement, respectively (Figure 1B). Among individuals who received a single MVA-129 BN injection (older individuals), none were responders in the absence of complement, while 45% were 130 responders in the presence of complement. There were no responders after one or two doses of MVA-131 BN (younger individuals) in assays without complement, whereas 27% and 44% were neutralizers at 132 these time points in the presence of complement. We detected 20% (2/10) and 50% neutralizers 133 among MVA-HIVB vaccinees in assays without and with complement, respectively (Figure 1B).

134 The Pan-PXV peptide pool elicits T-cell responses in MPXV-infected individuals and MVA-BN

135 and experimental MVA-HIVB vaccinees

136 We next assessed T-cell immune responses using the ex vivo IFN-y ELISpot assay and a 137 commercially available pan-poxviridae peptide pool containing selected sequences from monkeypox, 138 variola, and vaccinia viruses (Pan-PXV pool from JPT Peptide Technologies). The frequency of 139 responders was 88% (7/8) among MPXV-infected individuals. After one dose of MVA-BN, 50% (10/20) 140 and 53% (8/15) were responders among older and younger individuals, respectively. In the younger 141 group, 72% (13/18) were responders after the second vaccine dose. Eighty percent (8/10) were 142 responders after two doses of the MVA-HIVB vaccine (Figure 2A). We then compared T-cell 143 responses specific to Pan-PXV between MPXV-infected patients and individuals who received full 144 vaccination (1 or 2 doses, based on their history of smallpox vaccination during chidhood.) of MVA-145 BN, or two doses of MVA-HIVB. Infected patients showed a significantly higher median number of spot-forming cells (SFC/10⁶ cells) against the Pan-PXV pool than fully vaccinated MVA-BN individuals 146 147 (540 [160-1133] vs 96.5 [22-180], P=0.0071), whereas the magnitude was not significantly different 148 from that of recipients of MVA-HIVB (P=0.5829) (Figure 2B).

The functionality of Pan-PXV-specific CD4⁺ and CD8⁺ T-cell responses was assessed by intracellular cytokine staining (ICS) (Gating strategy is shown in supplementary Figure 2). We evaluated the production of IFN- γ , IL-2, TNF, and IL-4/IL-13/IL-10 (Th2/regulatory cytokines) by CD4⁺ T cells and IFN- γ , IL-2, and TNF by CD8⁺ T cells. Interestingly, only Pan-PXV-specific CD8⁺ T cells were detected *ex vivo*. The median [IQR] frequency of CD8⁺ T-cell responses was 0.67% [0.5-0.8] for MPXV-infected

154 individuals, 0.17% [0.1-0.2] for older individuals, 0.18% [0.1-0.2] and 0.18% [0.09-0.4] for younger 155 individuals after one or two doses, respectively, and 0.19% [0.1-0.5] for MVA-HIVB recipients (Figure 156 2C). These values were significantly different from those for unstimulated conditions (P<0.05) for all 157 comparisons. Globally, the median magnitude of CD8⁺ Pan-PXV-specific T cells was higher for 158 infected patients than for MVA-BN-vaccinated individuals (0.45% [0.3-0.6] vs 0.06% [0.04-0.14], 159 P=0.0155) (Figure 2D). Polyfunctional CD8⁺ T-cell specific responses to the Pan-PXV peptide pool 160 (producing up to 3 cytokines: IFN-γ± IL-2±TNF) were detectable in all groups. MPXV-infected 161 individuals exhibited a low frequency (6%) of CD8⁺ T cells simultaneously producing three cytokines 162 and 70% double positive IFN- γ^+ /TNF⁺ CD8⁺ T cells. Single positive CD8⁺ T cells were predominantly 163 IFN- γ^{+} . Older individuals who received one dose of MVA-BN vaccine showed a low frequency (6%) of 164 triple positive CD8⁺ T cells, a higher frequency of double positive (IFN- γ^{+} TNF⁺) (43%) CD8⁺ T cells and 165 similar levels of single IFN-y- and TNF-producing cells (23% for IFN-y and 21% for TNF). Younger 166 vaccinees exhibited clearly higher frequencies of triple- (25%) and double- (45%) positive CD8⁺ T cells 167 after one dose of MVA-BN. After two doses of the MVA-BN or MVA-HIVB vaccines, the functional 168 profiles of Pan-PXV CD8⁺ T cells were similar, with a high proportion of triple- (29% and 27%, 169 respectively) and double- (35% and 44%, respectively) positive CD8⁺ T cells (Figure 2C).

170 The MVA peptide pools elicit T-cell responses in MPXV-infected individuals and MVA-BN and

171 experimental MVA-HIVB vaccinees

We next used five PepMix pools (MVA-018L, MVA-074R, MVA-093L, MVA-105L, and MVA-121L), consisting of 15-mer peptides, overlapping by 11 amino acids, covering different proteins of MVA (Supplementary Table 1), to deeply characterize T-cell immune responses against vaccinia virus and enable a comprehensive comparison between individuals vaccinated with the MVA-BN and MVA-HIVB vaccines.

The MVA proteins exhibit a high degree of similarity with both the MVA-BN and MVA-HIVB vaccines (>99%) and with the vaccinia virus Lister strain (>98%) used in historical smallpox vaccinations. These MVA proteins show significant conservation in the MPXV 2022 sequences (>94%). We first evaluated the proportion of IFN- γ responders to the MVA global peptide pool (i.e., sum of the five Pepmix peptide pools) by *ex-vivo* IFN- γ ELISPOT assay. IFN- γ responders were 75% (6/8) for MPXV-infected individuals, 60% (12/20) for older individuals who received one dose of MVA-BN, and 60% (9/15) and

183 83% (15/18) for younger individuals after the first and second dose of the MVA-BN vaccine, 184 respectively. One hundred percent (10/10) in the two-dose MVA-HIVB vaccine group were 185 responders. The median magnitude (SFC/10⁶ cells) of the response was 107.5 [39-297] for 186 convalescent patients, 84.5 [25-195] for older individuals who received one dose, and 88 [34-236] and 187 221.5 [88-465] for younger individuals after one and two doses of MVA-BN vaccine, respectively. 188 Individuals fully vaccinated with the MVA-HIVB vaccine showed the highest response (248 SFC/10⁶ 189 cells [153-1010]) (Figure 3A).

190 We sought to assess the frequency of IFN- γ responders to individual peptide pools between the 191 various groups (Figure S1). We found a higher frequency of responders to the MVA-121L and MVA-192 018L peptide pools (41% and 34%, respectively) than to the MVA-093L, -074R, and -105L peptide 193 pools (18%, 12%, and 8%, respectively) (Figure 3B). We then analyzed the breadth of T-cell 194 responses among IFN-y responders within the five different MVA peptide pools. We found T-cell 195 responders to each MVA peptide pool, but with differences between groups. For example, we detected 196 T-cell responses against the MVA-105L peptide pool for younger individuals vaccinated with MVA-BN 197 and MVA-HIVB but not for MPXV-infected and older individuals with a history of smallpox vaccination 198 who received one dose of MVA-BN. Moreover, the MVA-105L peptide pool was mostly targeted by 199 individuals who received the MVA-HIVB vaccine (71%). The MVA-018L and MVA-093L peptide pools 200 were mainly targeted by individuals who received two doses of either the MVA-BN (33% and 25% 201 respectively) or MVA-HIVB (35% and 33%, respectively) vaccines. The MVA-074R peptide pool was 202 mostly targeted by MPXV-infected individuals (40%). Finally, responses against the MVA-121L peptide 203 pool were equally detected for all groups (Figure 3C).

The MVA-121L and MVA-018L peptide pools elicit polyfunctional CD4⁺ and CD8⁺ T-cell responses in MVA-vaccinated recipients

We further characterized the CD4⁺ and CD8⁺ T-cell responses induced by the MVA peptide pools by ICS (Figure 4 and supplementary figure 2 for representative dot plots). Responses were detected solely for vaccinees (MVA-BN and MVA-HIVB) and were dominated by two peptide pools: MVA-121L and MVA-018L. CD4⁺ T-cell responses to the MVA-121L peptide pool were significant (P<0.05 for all comparisons with non-stimulated conditions) for older (one dose) and younger (one and two doses) MVA-BN and MVA-HIVB (two doses) vaccinated individuals, with a high proportion of polyfunctional CD4⁺ T cells with a mixed cytokine profile simultaneously producing up to four cytokines (IFN- γ ±IL-

213 2±IL-4/IL-13/IL-10±TNF). Polyfunctional CD4⁺ T-cell frequencies ranged between 60% for younger 214 individuals who received one dose of MVA-BN to 76% for the MVA-HIVB vaccinees. Interestingly, the 215 functional profile of CD4⁺ T-cell responses against MVA-121L was similar for recipients of two doses 216 of MVA-BN or MVA-HIVB. Among specific CD4⁺ T cells producing only one cytokine, CD4⁺TNF⁺ cells 217 were predominant (Figure 4A). Two doses of MVA-BN and MVA-HIVB vaccines elicited MVA-121L-218 specific CD8⁺T cells (P=0.02 and P=0.004 compared to unstimulated conditions, respectively), with 219 mostly IFN- γ^+ single positive CD8⁺ T cells (Figure 4B). In addition to MVA-121L, MVA-018L also 220 induced detectable CD8⁺ T-cell responses following two doses of the MVA-BN and MVA-HIVB 221 vaccines (P=0.0009 and P<0.0001 compared to unstimulated conditions, respectively), with a 222 predominant proportion of polyfunctional CD8⁺ T cells simultaneously producing up to three cytokines 223 (47% and 66% for MVA-BN and MVA-HIVB, respectively). Among specific CD8⁺ T cells producing two 224 cytokines, the profile was similar for both groups, consisting mostly of IFN-y/TNF-producing cells. The 225 frequencies of IFN- γ^+ single-positive CD8⁺ T cells were 49% for the MVA-BN group and 28% for the 226 MVA-HIVB group (Figure 4B).

227 MVA-BN vaccination in HIV-positive and HIV-negative Individuals

Finally, we evaluated the immune response of PLWHIV under successful antiretroviral therapy to MVA-BN vaccination. We found NAb titers against MVA and MPXV, as well as T-cell responses against the Pan-PXV and MVA peptide pools, for fully MVA-BN-vaccinated PLWHIV to not be significantly different from those of non-HIV-infected individuals, either after one (for older individuals) or two doses (for younger individuals) (Figure 5).

234 Discussion

235 The recent outbreak of mpox infection has revitalized questions about the quality and durability of 236 humoral and cellular responses against OPXV and the efficacy of the approved MVA-based vaccine 237 (IMVANEX) deployed since May 2022 for populations at risk of infection. We analyzed antibody and 238 cellular responses against MPXV and MVA in subjects infected during the recent mpox-2022 outbreak 239 or vaccinated with the MVA-BN (IMVANEX) vaccine or an experimental MVA-HIVB vaccine (ANRS/VRI01 trial; NCT02038842) ³². We provide insights about the cross reactivity of the humoral 240 241 and cellular responses induced by MVA-based vaccination and MPXV infection and the impact of 242 historical smallpox vaccination on cellular immunity following MPXV infection or MVA vaccination, in 243 particular among PLWHIV.

244 To study protective antibody-based immunity, we measured Nabs against MVA and MPXV. As 245 recently shown ^{31, 33}, the presence of complement enhanced the sensitivity of Nab detection. We found 246 a higher frequency of MPXV and MVA responders among MPXV-infected individuals (88-100%) three 247 weeks after the onset of symptoms than among individuals vaccinated with MVA. The proportion of 248 MVA neutralizers among the recipients of two doses of MVA-HIVB or MVA-BN was roughly similar 249 (90% and 94%, respectively), whereas the MVA Nab titers were approximately 2.2-fold higher after the 250 second dose of MVA-HIVB than that of MVA-BN. Despite homology between MVA and MPXV, only 251 around 45% of fully vaccinated older and younger MVA-BN-vaccinated individuals exhibited weak 252 MPXV neutralization activity, a frequency similar to that for MVA-HIVB vaccinees (50%). Thus, despite 253 potential differences in the MVA-BN and MVA-HIVB strains, preparation methods, and doses 254 administered, these two vaccines elicited strong and similar humoral responses against MVA and 255 MPXV. This observation supports the development of future MVA-based vaccines against MPXV³⁴.

One dose of MVA-BN led to a higher frequency of MVA neutralizers and higher titers (8.5-fold) for individuals born before 1980 than those born after (95% versus 26%), underscoring the importance of childhood smallpox vaccination. Smallpox vaccination of the French population stopped in 1979 and smallpox was declared to be eradicated worldwide in 1980. Our observation suggests that MVA-BN recalled long-term memory B-cell responses and supports the persistence of smallpox-specific B cells in the absence of re-exposure to smallpox antigens. Several studies have demonstrated the presence of long-lived smallpox-specific B cells up to 50 to 75 years after vaccination ^{22, 35, 36, 37} and the stability

of anti-vaccinia antibody serum titers in humans for more than 80 years after first vaccination ^{17, 20, 37}. Finally, the significant increase in the rate of MVA (from 26% to 72%) and MPXV (0% to 44%) responders following a second boost of MVA-BN among younger individuals reinforces the need of a complete vaccination scheme to improve protective immunity in a "naïve" population.

267 In humans, it is likely that both humoral and cell-mediated immunity are important for protection 268 against OPXV. Few studies have investigated or compared cellular immune responses to MPXV- and MVA-based vaccines ^{27, 28} and more in-depth analyses of the antigens recognized by T cells are 269 270 warranted. In parallel to neutralizing antibody responses, we found a higher frequency and magnitude 271 (5-fold) of T-cell responses against peptide pools containing selected sequences from MPXV, variola, 272 and vaccinia viruses (Pan-PXV) for MPXV-infected than MVA-vaccinated individuals. ICS assay 273 showed that this response was mediated by CD8 T cells. This observation differs from those of a recent study ²⁷ and can be explained by two principal factors. First, the cellular assays used; Cohn and 274 275 colleagues adopted a combined AIM/ICS assay while we employed a two-step approach, starting with 276 an IFN-g ELISpot and subsequently using ICS assays, despite the latter being less sensitive in 277 comparison to an AIM assay. Our aim in employing this strategy was to deeply characterize the 278 functionality of mpox-specific CD4 and CD8 T cells, rather than solely focusing on assessing the 279 frequency of these cell populations. Secondly, the composition of the peptide pools, they used 2 280 megapools (one megapool of 238 CD8 T-cell epitopes, of which 82% are 100% conserved in MPXV, 281 and another megapool of 300 CD4 T-cell epitopes, of which 94% are 100% conserved in MPXV). In 282 contrast, we employed a Pan-PXV peptide pool containing 127 epitopes, comprising 107 CD8 T-cell 283 epitopes and 20 CD4 T-cell epitopes, with 96% exhibiting complete conservation in MPXV and 94% in 284 MVA.

In contrast to antibody responses, the frequency of T-cell responders following the administration of MVA-BN was found to be the same for both older and younger vaccinated individuals (approximately 50%). This suggests that the impact of smallpox vaccination in childhood on T-cell responses may be relatively low. Analysis of the quality of Pan-PXV specific T cells showed these responses to be mainly mediated by CD8⁺ T cells and confirmed a higher frequency of such T-cell responses among MPXVinfected individuals. Interestingly, MPXV infection was characterized by a high frequency of CD8⁺ cells simultaneously producing TNF/IFN-γ, whereas full vaccination with IMVANEX and MVA-HIVB induced

292 a higher frequency of polyfunctional Th1 CD8⁺ T cells simultaneously producing three cytokines (IL-293 $2+IFN-\gamma+TNF$).

Despite high genetic similarity between MVA and MPXV-2022 ^{28, 38}, the potential impact of variations in 294 295 T-cell epitopes on the cross reactivity induced by MVA-based vaccination and MPXV infection is yet to 296 be determined. To analyze the cross-reactivity of T-cell responses in more depth, we selected five 297 pools of peptides spanning five highly homologous regions between the two MVA vaccines and the 298 original vaccinia Lister strain used in historical smallpox vaccination (>98%) and MPXV 2022 299 sequences (>94%). Using the Elispot-iFN- γ assay as a screening test, we found a hierarchy of T-cell 300 responses against these peptide pools ranging from MVA-121L and MVA-018L (41% and 34% 301 responders, respectively) to MVA-105L (8% responders). Indeed, the MVA-121L protein corresponds 302 to the A10L vaccinia protein and is known to contain a high number of T-cell epitopes (27 CD4⁺ and 1 CD8⁺ T-cell epitopes) ^{28, 38}, which are highly conserved (100%) in MVA-BN (21 epitopes) and MPX-303 304 2022 (25 epitopes). MVA-018L corresponds to the C7L vaccinia protein and contains two CD8⁺ T-cell epitopes ^{28, 38}, including one (KVDDTFYYV) that is relatively dominant in HLA-A2⁺ individuals ³⁹. The 305 306 observed lower frequency of responders to MVA-18L among MPXV-infected patients relative to MVA-307 vaccinated individuals can be explained by the presence of the D77Y mutation in this dominant 308 epitope in the MPXV-2022 sequence. Similarly, the frequency of T-cell responders to the MVA-093L 309 peptide pool, which targets the H3L vaccinia protein, among MPXV-infected individuals was low, despite the presence of eight CD4⁺ and four CD8⁺ T-cell epitopes ^{28, 38}. However, nine of these 12 310 311 epitopes contain at least one mutation in the MPXV-2022 sequence. Finally, T-cell responses to the 312 MVA-105L (corresponding to the D8L vaccinia protein) peptide pool were infrequent among MVA-313 vaccinated individuals (8%) and not detected among MPXV-infected subjects. This is consistent with a single described CD4⁺ T-cell epitope in this protein ^{28, 38}, which contains two mutations in the MPXV-314 315 2022 sequence. Overall, although the peptide regions exhibit significant homology, the variations 316 observed among different groups of individuals align with the distinctions observed between the 317 evolution of MVA and MPXV. Beyond a descriptive profile of T-cell responses, these data help to 318 enrich the arsenal of peptide tools for the future immunological evaluation of OPXV infection and 319 vaccination.

320 The potential threat of the reemergence of smallpox following an act of bioterrorism or of MPXV raises 321 the question of the diversification and availability of potent vaccines. We took the opportunity to 322 analyze B- and T-cell responses against the MVA vector of participants who received two doses of an MVA-based HIV vaccine candidate (MVA- HIVB) in the ANRS VRI01 trial ³². We show ³¹ and confirm 323 324 that the MVA-HIVB vaccine elicits somewhat higher levels of anti-MVA Nabs in individuals born before 325 1980 than after IMVANEX administration. Moreover, we extend these data, showing that both 326 vaccines induce a high frequency of polyfunctional CD4⁺ and CD8⁺ T-cell responses against MVA-327 121L and MVA-018L, with a high proportion of polyfunctional CD4⁺ T cells with a mixed cytokine 328 profile simultaneously producing up to four Th1/Th2 cytokines, a population of cells described in smallpox vaccination ⁴⁰. Overall, the T-cell responses triggered by two doses of MVA-HIVB were either 329 330 similar or occurred at a higher frequency than those to MVA-BN. These findings provide reassurance 331 concerning the potential production of clinical batches of this vector, if needed.

332 Although our study was not designed to compare the potency of vaccination between different groups 333 of patients, we were able to show that Nab titers against both MVA and MPXV, as well as T-cell 334 responses against the Pan-PXV and MVA peptide pools, were not impaired in PLWHIV, regardless of 335 age. It's worth noting that individuals infected with HIV-1 who participated in this study were 336 undergoing antiretroviral therapy and maintained a robust immune profile, characterized by CD4 T 337 lymphocyte counts exceeding 200 cells/mm3 and an undetectable plasma HIV RNA viral load (below 338 20 copies/ml). This favorable immunological status may account for the absence of differences in 339 vaccine response magnitude when compared to individuals without HIV infection. Although reassuring, 340 these data should be viewed in light of the recent observation of MPXV reinfection in previously 341 vaccinated individuals and underscore the need to repeat boosting according to recent 342 recommendations.

This study had several limitations. Individuals were enrolled after infection (three weeks, on average, after symptoms) and following vaccination. We did not evaluate their baseline immune status. However, the results within each group were homogeneous and allowed statistical comparisons between groups. We evaluated the levels of neutralizing antibodies, but we did not assess the levels of antigen-binding antibodies. Additionally, we did not evaluate antibody effector functions due to the unavailability of standardized kits for conducting these specific assays. We describe T-cell responses

against peptides pools but did not perform epitope mapping because of the limited amount of the blood samples and lack of patient HLA information. We assessed T-cell responses using ex vivo stimulations. The lack of response in some cases may be attributed to the lower sensitivity of the ex vivo ICS assay. However, we also conducted an ELISPOT assay, which has a high level of sensitivity, even though it cannot distinguish between CD4 and CD8 responses. Finally, we did not perform longterm follow up of B- or T-cell responses to assess the durability of the responses, either for MPXVinfected individuals or MVA-vaccinated individuals.

357	Referer	nces
358		
359 360	1. molecul	Wang L, Shang J, Weng S, Aliyari SR, Ji C, Cheng G, et al. Genomic annotation and ar evolution of monkeypox virus outbreak in 2022. Journal of Medical Virology 2022, 95(1).
361		
362 363	2. Death ir	Alarcón J, Kim M, Terashita D, Davar K, Garrigues JM, Guccione JP, et al. An Mpox-Related the United States. New England Journal of Medicine 2023, 388(13): 1246-1247.
364		
365 366	3. Bmj 202	Mahase E. Mpox: Clinicians identify severe form with high mortality in advanced HIV patients. 23: p422.
367		
368 369 370	4. Mpox in 949.	Mitjà O, Alemany A, Marks M, Lezama Mora JI, Rodríguez-Aldama JC, Torres Silva MS, et al. people with advanced HIV infection: a global case series. The Lancet 2023, 401(10380): 939-
371		
372 373 374	5. Virus In 2022, 38	Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al. Monkeypox fection in Humans across 16 Countries — April–June 2022. New England Journal of Medicine 87(8): 679-691.
375		
376 377	6. The Lar	Poland GA, Kennedy RB, Tosh PK. Prevention of monkeypox with vaccines: a rapid review. ncet Infectious Diseases 2022, 22(12): e349-e358.
378		
379	7.	Volz A, Sutter G. Modified Vaccinia Virus Ankara. 2017, 97: 187-243.
380		
381 382	8. smallpo	Damon IK, Davidson WB, Hughes CM, Olson VA, Smith SK, Holman RC, et al. Evaluation of x vaccines using variola neutralization. Journal of General Virology 2009, 90(8): 1962-1966.
383 384 385	9. safety a Vaccine	Frey SE, Newman FK, Kennedy JS, Ennis F, Abate G, Hoft DF, et al. Comparison of the and immunogenicity of ACAM1000, ACAM2000 and Dryvax® in healthy vaccinia-naive adults. 2009, 27(10): 1637-1644.
386		
387 388 389	10. respons challenç	Frey SE, Newman FK, Kennedy JS, Sobek V, Ennis FA, Hill H, et al. Clinical and immunologic ses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® ge. Vaccine 2007, 25(51): 8562-8573.
390		

391 11. Overton ET, Lawrence SJ, Stapleton JT, Weidenthaler H, Schmidt D, Koenen B, et al. A
 392 randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at
 393 various doses in adults with a history of AIDS. Vaccine 2020, 38(11): 2600-2607.

394

Pittman PR, Hahn M, Lee HS, Koca C, Samy N, Schmidt D, et al. Phase 3 Efficacy Trial of
Modified Vaccinia Ankara as a Vaccine against Smallpox. New England Journal of Medicine 2019,
381(20): 1897-1908.

398

13. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, et al. Immunogenicity of a
highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004, 428(6979):
182-185.

402

403 14. Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K, et al. Rapid protection in a
404 monkeypox model by a single injection of a replication-deficient vaccinia virus. Proceedings of the
405 National Academy of Sciences 2008, 105(31): 10889-10894.

406

Hatch GJ, Graham VA, Bewley KR, Tree JA, Dennis M, Taylor I, et al. Assessment of the
Protective Effect of Invamune and Acam2000 Vaccines against Aerosolized Monkeypox Virus in
Cynomolgus Macaques. Journal of Virology 2013, 87(14): 7805-7815.

410

411 16. Wolff Sagy Y, Zucker R, Hammerman A, Markovits H, Arieh NG, Abu Ahmad W, et al. Real412 world effectiveness of a single dose of mpox vaccine in males. Nature Medicine 2023, 29(3): 748-752.

413

Taub DD, Ershler WB, Janowski M, Artz A, Key ML, McKelvey J, et al. Immunity from
Smallpox Vaccine Persists for Decades: A Longitudinal Study. The American Journal of Medicine
2008, 121(12): 1058-1064.

417

418 18. Golden J, Harryman L, Crofts M, Muir P, Donati M, Gillett S, et al. Case of apparent mpox
419 reinfection. Sexually Transmitted Infections 2023, 99(4): 283-284.

420

Jamard S, Handala L, Faussat C, Vincent N, Stefic K, Gaudy-Graffin C, et al. Resurgence of
symptomatic Mpox among vaccinated patients: First clues from a new-onset local cluster. Infectious
Diseases Now 2023, 53(4): 104714.

424	
425 426	20. Amanna IJ, Slifka MK, Crotty S. Immunity and immunological memory following smallpox vaccination. Immunological Reviews 2006, 211(1): 320-337.
427	
428 429 430	21. Combadiere B, Boissonnas A, Carcelain G, Lefranc E, Samri A, Bricaire Fo, et al. Distinct Time Effects of Vaccination on Long-Term Proliferative and IFN-γ–producing T Cell Memory to Smallpox in Humans. Journal of Experimental Medicine 2004, 199(11): 1585-1593.
431	
432 433 434	22. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination. The Journal of Immunology 2003, 171(10): 4969-4973.
435	
436 437	23. Demkowicz WE, Littaua RA, Wang J, Ennis FA. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. Journal of Virology 1996, 70(4): 2627-2631.
438	
439 440	24. Kennedy JS, Greenberg RN. IMVAMUNE®: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Review of Vaccines 2014, 8(1): 13-24.
441	
442 443 444 445	25. Cosma A, Bu hler S, Nagaraj R, Staib C, Hammarin A-L, Wahren B, et al. Neutralization Assay Using a Modified Vaccinia Virus Ankara Vector Expressing the Green Fluorescent Protein Is a High-Throughput Method To Monitor the Humoral Immune Response against Vaccinia Virus. Clinical and Vaccine Immunology 2004, 11(2): 406-410.
446	
447 448 449	26. Zaeck LM, Lamers MM, Verstrepen BE, Bestebroer TM, van Royen ME, Götz H, et al. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nature Medicine 2022, 29(1): 270-278.
450	
451 452 453	27. Cohn H, Bloom N, Cai GY, Clark JJ, Tarke A, Bermúdez-González MC, et al. Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study. The Lancet Infectious Diseases 2023.

454

455 28. Grifoni A, Zhang Y, Tarke A, Sidney J, Rubiro P, Reina-Campos M, et al. Defining antigen
456 targets to dissect vaccinia virus and monkeypox virus-specific T cell responses in humans. Cell Host &
457 Microbe 2022, 30(12): 1662-1670.e1664.

458

459 29. Agrati C, Cossarizza A, Mazzotta V, Grassi G, Casetti R, De Biasi S, et al. Immunological
460 signature in human cases of monkeypox infection in 2022 outbreak: an observational study. The
461 Lancet Infectious Diseases 2023, 23(3): 320-330.

462

463 30. Adamo S, Gao Y, Sekine T, Mily A, Wu J, Storgärd E, et al. Memory profiles distinguish cross464 reactive and virus-specific T cell immunity to mpox. Cell Host & Microbe 2023, 31(6): 928-936.e924.

465

466 31. Hubert M, Guivel-Benhassine F, Bruel T, Porrot F, Planas D, Vanhomwegen J, et al.
467 Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals. Cell
468 Host & Microbe 2023, 31(6): 937-948.e934.

469

32. Richert L, Lelièvre J-D, Lacabaratz C, Hardel L, Hocini H, Wiedemann A, et al. T Cell
Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost
Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm
Phase I/II ANRS VRI01 Trial. The Journal of Immunology 2022, 208(12): 2663-2674.

474

475 33. Yefet R, Friedel N, Tamir H, Polonsky K, Mor M, Cherry-Mimran L, et al. Monkeypox infection
476 elicits strong antibody and B cell response against A35R and H3L antigens. iScience 2023, 26(2):
477 105957.

478

34. Raadsen MP, Dahlke C, Fathi A, Lamers MM, van den Doel P, Zaeck LM, et al. Monkeypox
Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia
Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein. The Journal of
Infectious Diseases 2023.

483

Chappert P, Huetz F, Espinasse M-A, Chatonnet F, Pannetier L, Da Silva L, et al. Human antismallpox long-lived memory B cells are defined by dynamic interactions in the splenic niche and longlasting germinal center imprinting. Immunity 2022, 55(10): 1872-1890.e1879.

Gilchuk I, Gilchuk P, Sapparapu G, Lampley R, Singh V, Kose N, et al. Cross-Neutralizing and
Protective Human Antibody Specificities to Poxvirus Infections. Cell 2016, 167(3): 684-694.e689.

490

491 37. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, et al. Duration of
492 antiviral immunity after smallpox vaccination. Nature Medicine 2003, 9(9): 1131-1137.

493

494 38. Ahmed SF, Sohail MS, Quadeer AA, McKay MR. Vaccinia-Virus-Based Vaccines Are
495 Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus. Viruses 2022, 14(9):
496 1960.

497

39. Terajima M, Orphin L, Leporati AM, Pazoles P, Cruz J, Rothman AL, et al. Vaccinia virusspecific CD8+ T-cell responses target a group of epitopes without a strong immunodominance
hierarchy in humans. Human Immunology 2008, 69(12): 815-825.

501

40. Anderson EJ, Lai L, Wrammert J, Kabbani S, Xu Y, Priyamvada L, et al. Plasmablast, Memory
B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified
Vaccinia Ankara Vaccine. Vaccines 2020, 8(1): 69.

505

506 41. Roederer M, Nozzi JL, Nason MC. SPICE: Exploration and analysis of post-cytometric 507 complex multivariate datasets. Cytometry Part A 2011, 79A(2): 167-174.

508

510 Data availability

- 511 All data supporting the findings of this study are available within the paper and its Supplementary
- 512 Information. Raw data are available from the corresponding author upon reasonable request
- 513

514 Acknowledgments

- 515 The authors thank the individuals and patients who participated in this study and Véronique Rieux
- 516 (ANRS-MIE) and Lucie Hardel for their help with the ANRS-VR01 trial samples.

517 Contributors

- 518 Yves Lévy, Aurélie Wiedemann, and Mathieu Surénaud conceived and designed the study. Yves
- 519 Lévy, Aurélie Wiedemann, Mathieu Surénaud, Mathieu Hubert, Jean-Daniel Lelièvre, and Olivier
- 520 Schwartz analyzed and interpreted the data. Mathieu Hubert, Alexandre Ribeiro, Cécile Rodrigues,
- 521 Emile Foucat, and Corinne Krief performed the experiments. José-Luis Zaragoza and Harouna
- 522 Diombera participated in sample and clinical data collection. Yves Lévy, Aurélie Wiedemann, and
- 523 Mathieu Surénaud drafted the first version and wrote the final version of the manuscript. All authors
- 524 approved the final version.

525 Funding

- 526 This work was supported by INSERM and the Investissements d'Avenir program, Vaccine Research
- 527 Institute (VRI), managed by the ANR under reference ANR-10-LABX-77-01.

528 Declaration of interest

- 529 The authors declare no conflict of interest.
- 530
- 531

532 Materials and Methods

533 Participants

534 In July 2022, a prospective, monocentric cohort clinical study enrolling MPXV infected patients and 535 individuals vaccinated with a third-generation MVA-based vaccine (IMVANEX) was initiated by the 536 Immunology Department of the Henri Mondor Hospital. The study protocol was approved by the 537 appropriate ethics committee (CPP Ile-de-France VII and IX), with approval reference 10-023 538 (infected patients) and ID RCB 2018_A01610-55 - n°CPP:18.09.09 (vaccinated patients). Written 539 informed consent was collected from each participant at enrollment. In addition, we used samples from 540 subjects enrolled in the ANRS VRI01 clinical trial, a trial performed in 2014 on 92 individuals to 541 evaluate the effectiveness of MVA-HIVB as a vaccine candidate. Each participant was injected with 542 two doses of MVA-HIVB with an eight-week interval. The protocol was approved by an ethics 543 committee (Comité de Protection des Personnes Ile-de-France V, Paris, France) and the competent 544 French health authority (Agence Nationale de Sécurité du Médicament et des Produits de Santé) and 545 was conducted in accordance with the declaration of Helsinki. All volunteers provided written and 546 signed informed consent for the trial. The trial was registered with ClinicalTrials.gov (NCT02038842) and EudraCT (2012-002456-17) 32. 547

548 MVA and MPXV neutralization assays

Seroneutralization assays against MVA and MPXV were performed as previously described ³¹. Briefly, 549 550 a modified Vaccinia virus Ankara carrying a GFP reporter gene (MVA-GFP) was provided by ANRS-551 MIE. A MPXV strain (MPXV/2022/FR/CMIP) was isolated from a pustular lesion of a 36- year-old 552 French man who consulted at the Medical Center of the Institut Pasteur (CMIP), in June 2022. For the 553 MVA neutralization assay, Vero E6 cells were used. The indicated concentrations of MVA-GFP were 554 mixed (ratio 1:1) with serial dilutions (from 1/30 to 1/30,000) of previously heat-inactivated (30 min at 555 56°C) plasma or serum in the presence or absence of 10% guinea pig serum as a source of 556 complement (GPC; Rockland). After incubation for 2 h at 37°C, the mixture was added to Vero E6 cell 557 monolayers. Twenty hours later, cells were stained with Hoechst (1:1,000 dilution; Invitrogen). Images 558 were acquired using an Opera Phenix high-content confocal microscope (Perkin Elmer). The GFP 559 area and number of nuclei were quantified using Harmony software (Perkin Elmer). The percentage of 560 neutralization was calculated using the GFP area as the value with the following formula: 561 100 x (11-- (value for serum - value for "non-infected")/(value for "no serum" - value for "non-

562 infected")). The neutralizing activity of each plasma or serum sample was expressed as the ED50 563 (effective dose inhibiting 50% of infection). ED50 values were calculated using a reconstructed curve 564 with the percentage of neutralization at the different serum concentrations. For the MPXV 565 neutralization assay, U2OS cells were used. The indicated concentrations of MPXV were mixed (ratio 566 1:1) in a BSL-3 facility with serial dilutions of previously heat-inactivated (30 min at 56°C) plasma or 567 serum in the presence or absence of 10% GPC. Forty-eight hours later, cells were immunostained for 568 MPXV antigens with rabbit polyclonal anti-VACV antibodies (PA1-7258, Invitrogen) and an Alexa Fluor 569 488-coupled goat anti-rabbit antibody (Invitrogen). Nuclei were stained with Hoechst. Images were 570 acquired using an Opera Phenix high-content confocal microscope (PerkinElmer). The MPXV⁺ area 571 and number of nuclei were quantified using Harmony software (PerkinElmer). The neutralization titer 572 was determined as the highest plasma or serum dilution in which the MPXV⁺ area was inferior to that 573 of the "no serum" condition. The proportion of neutralizers was then evaluated by calculating the 574 percentage of individuals exhibiting a neutralizing activity > LOD (limit of detection).

575 Specific antigens

576 To evaluate the anti-Vaccinia and anti-Monkeypox virus cellular immune responses, screening 577 experiments (IFN-y ELISpot) were performed using six peptide pools from Vaccinia virus strain Ankara (PepMix MVA-018L, MVA-074R, MVA-093L, MVA-105L, MVA-121L, and MVA-189R) and one from 578 579 Vaccinia virus strain Western Reserve (PepMix VACV-L3L). These pools consist of 15-mer peptides, 580 overlapping by 11 amino acids, covering different proteins of the Vaccinia virus. In addition, the Pan-581 Poxviridae Select PepMix, containing 127 selected epitopes (composed of 107 CD8 T-cell epitopes 582 and 20 CD4 T-cell epitopes, of which 96% are 100% conserved in MPXV and 94% are 100% 583 conserved in MVA) from the Monkeypox virus, Variola virus, and Vaccinia virus, was used. The 584 peptide pools were all purchased from JPT Peptide Technologies, Berlin, Germany. As the sequence 585 homology of Putative 21.7k protein (MVA189R) was below 90% between MVA and MPXV and as no 586 responder was observed with VACV-L3L in screening experiments, these two peptide pools were not 587 used in later experiments. The five remaining MVA peptide pools used in this study are described in 588 Supplementary Table 1.

589 IFN-γ Elispot assay

590 Ag-specific T cell responses were assessed using an IFN- γ ELISpot assay (ELISpot plus: Human IFN-591 γ (ALP), Mabtech) on cryopreserved PBMCs following the manufacturer's instructions. Thawed

PBMCs were stimulated (100,000 cells/well) for 18 h at 37°C, 5% CO₂ with 2 μg/ml of the 6 PepMix as described previously. Non-stimulated PBMCs were used as a negative control and anti-CD3- (1/2000) stimulated PBMCs were used as a positive control. Spot-forming cells (SFC) were counted using an AID ELISpot reader (AID Autoimmun Diagnostika GmbH) and are expressed as SFC/10⁶ cells after deduction of the background (non-stimulated PBMCs). Seventy-eight samples were tested, and the positivity threshold was defined as three-fold the mean of all non-stimulated PBMCs (52 SFC/10⁶ cells) after deduction of the background.

599 Intracellular Staining (ICS) assay

The quality of Ag-specific T-cell responses was evaluated using an intracellular cytokine staining (ICS) assay on cryopreserved PBMCs. PBMCs were stimulated (18h, 37°C, 5% CO₂) with the six peptide pools as described above in the presence of anti-CD28 and anti-CD49d Abs (1 μ g/ml each) and GolgiPlug (10 μ g/ml) (BD Biosciences, Le Pont de Claix, France). Cell functionality was assessed by ICS, with Boolean gating. The flow cytometry panel included a viability marker, CD3, CD4, and CD8 antibodies to determine the T-cell lineage, and IFN- γ , TNF, IL-2, IL-4, IL-10, IL-13 antibodies (all from BD Biosciences).

Data were acquired using a LSRFortessa four-laser (488, 640, 561, and 405 nm) flow cytometer (BD
 Biosciences) and analyzed using FlowJo software, version 9.9.5 (Tree Star). Distributions were plotted
 with SPICE version 5.22, downloaded from http://exon.niaid.nih.gov/spice

610 Statistical analysis

Figures and statistical analyses were conducted using GraphPad Prism 9. Statistical significance between groups was calculated using the tests indicated in each figure legend. No statistical methods were used to predetermine sample size.

614

616 Figure legends

617 Figure 1. Neutralizing antibodies induced by MPXV infection and the MVA-BN and experimental 618 MVA-HIVB vaccines. A. Seroneutralization of MVA-GFP and B. MPXV by sera from MPXV-infected 619 patients (Conv.) (n=8) and MVA-BN- and MVA-HIVB vaccinees in the presence or absence of 10% 620 guinea pig complement as a source of complement. Younger and older individuals were distinguished 621 using 1980 as a cut-off year. In the vaccine groups, individuals were separated according to their 622 vaccination status at the time of sample collection (1d: after the first dose (n=20 and n=15 for 623 individuals born <1980 and >1980, respectively); 2d: after the second dose (n=18 and n=10, for the 624 MVA-BN and MVA-HIVB vaccines, respectively). Anti-MVA neutralizing activity is expressed as the 625 median effective dose (ED50), corresponding to the last dilution of plasma that reduces MVA-GFP 626 infection by 50%. Anti-MPXV neutralizing activity is expressed as the neutralizing titer, corresponding 627 to the highest dilution for which neutralization was observed. The dotted line represents the limit of 628 detection (LOD). The proportion of neutralizers was evaluated by calculating the percentage of 629 individuals exhibiting a neutralizing activity > LOD. Kruskal Wallis' test was used for comparisons in 630 assays performed with complement.

631 Figure 2. Frequency and magnitude of T-cell responses against the Pan-PXV pool of peptides 632 induced by MPXV infection and the MVA-BN and MVA-HIVB vaccines. A. Magnitude of T-cell responses (SFC/10⁶ cells) of MPXV-infected patients (Conv) (n=8) and MVA-BN vaccinees (n=20 and 633 634 n=15 after the first dose (1d) for individuals born <1980 and >1980, respectively, n=18 after the 635 second dose (2d)), and MVA-HIVB vaccinees (n=10) against the Pan-PXV peptide pool measured by 636 the IFN-y ELISPOT assay. Background-subtracted results are presented. The dotted line represents the positivity threshold. B. T-cell responses (SFC/10⁶ cells) of MPXV-infected patients (Conv) (n=8), 637 638 fully vaccinated MVA-BN individuals (n=38), and MVA-HIVB vaccinees (n=10) against the Pan-PXV 639 peptide pool measured by IFN-y ELISPOT assay. Background-subtracted results are shown, with the 640 dotted line representing the positivity threshold. C. Magnitude and functional profile of Pan-specific 641 CD8⁺ T-cell responses of MPVX-infected patients (Conv) (n=6) or MVA-BN vaccinees (n=10 and n=15 642 after the first dose (1d) for individuals born <1980 and >1980, respectively; n=14 after the second 643 dose (2d)) and MVA-HIVB vaccinees (n=10) after overnight stimulation with the Pan-PXV peptide 644 pool. The median frequency of total cytokines detected (Cyt.Tot.) (IFN-γ±IL-2±TNF)±IQR is shown. 645 Wilcoxon comparison tests were used for statistical analysis. In the pie charts, responses are color

coded according to the combinations of cytokines produced. The arcs identify cytokine-producing subsets (IFN- γ , IL-2, and TNF) within the CD8⁺ T-cell populations. **D.** Magnitude of Pan-specific CD8⁺ T-cell responses of MPXV-infected (Conv) patients (n=6), fully vaccinated MVA-BN individuals (n=24), and MVA-HIVB vaccinees (n=10) after overnight stimulation with the Pan-PXV peptide pool. The median frequency of total cytokines detected (Cyt.Tot.) (IFN- $\gamma \pm$ IL-2 \pm TNF) \pm IQR is presented. Background-subtracted results are shown. Kruskal-Wallis and Dunn's comparison tests were used for statistical analysis.

653 Figure 3. Frequency and magnitude of T-cell responses against the MVA peptide pool induced 654 by MPXV infection and the MVA-BN and experimental MVA-HIVB vaccines. A. Magnitude of T-655 cell responses (SFC/10⁶ cells) of MPXV-infected patients (Conv) (n=8) and MVA-BN vaccinees (n=20 656 and n=15 after the first dose (1d) for individuals born <1980 and >1980, respectively, n=18 after the 657 second dose (2d)) and MVA-HIVB vaccinees (n=18) against the MVA global peptide pool (sum of 5 658 peptide pools) measured by IFN-y ELISPOT assay. Background-subtracted results are presented. The 659 dotted line represents the positivity threshold. Medians \pm IQR are shown. **B.** Frequency of IFN- γ 660 responders measured by ELISPOT assay to the MVA-18L, -121L, -093L, -074R, and -105L individual 661 peptide pools in each group of individuals. C. Breadth of T-cell responses against the MVA-18L, -662 121L, -093L, -074R, and -105L peptide pools among IFN-γ responders.

663 Figure 4. Polyfunctional CD4 and CD8 T-cell responses against the MVA-121L and MVA-018L 664 peptide pools induced by MVA vaccination. A. Magnitude and functional composition of MVA-665 121L-specific CD4⁺ T-cell responses of MVA-BN and MVA-HIVB vaccinees. B. Magnitude and 666 functional composition of MVA-121L- and MVA-018L-specific CD8⁺ T-cell responses of MVA-BN and 667 MVA-HIVB vaccinees (n=10 and n=15 after the first dose (1d) for individuals born <1980 and >1980, 668 respectively and n=14 after the second dose (2d)) for MVA-BN vaccinees; and n=10 for MVA-HIVB 669 vaccinees) after overnight stimulation with five pools of overlapping peptides covering different regions 670 of MVA. The median frequency of total cytokines (Cyt.Tot.) (IFN-g±IL-2±TNF) ± IQR is shown. 671 Friedman and Dunn's multiple comparison tests were used for statistical analysis. In the pie charts, 672 responses are color coded according to the combinations of cytokines produced. The arcs identify 673 cytokine-producing subsets within the CD4⁺ T-cell populations (IFN-y, IL-2, IL-4/IL-13/IL-10, and TNF) 674 and CD8⁺ T-cell populations (IFN-y, IL-2, and TNF).

675 Figure 5. Neutralizing antibodies and T-cell immune responses elicited by MVA-BN vaccination 676 in HIV-positive and HIV-negative Individuals. A. Seroneutralization of MVA-GFP (left panel) by sera 677 from HIV⁻ and HIV⁺ MVA-BN vaccinees in the presence of 10% guinea pig complement as a source of 678 complement. The anti-MVA neutralizing activity is expressed as the median effective dose (ED50), 679 corresponding to the last dilution of plasma that reduces MVA-GFP infection by 50%. Magnitude of Tcell responses (SFC/10⁶ cells) (right panel) of HIV⁻ and HIV⁺ MVA-BN vaccinees against the MVA 680 681 peptide pool measured by IFN-y ELISPOT assay. Background-subtracted results are presented. B 682 Seroneutralization of MPXV (left panel) by sera from HIV⁻ and HIV⁺ MVA-BN-vaccinees in the 683 presence of 10% guinea pig complement as a source of complement. Anti-MPXV neutralizing activity 684 is expressed as the neutralizing titer, corresponding to the highest dilution for which neutralization was observed. Magnitude of T-cell responses (SFC/10⁶ cells) (right panel) of HIV⁻ and HIV⁺ MVA-BN 685 686 vaccinees against the Pan-PXV peptide pool measured by IFN-y ELISPOT assay. (HIV⁻ n=21, HIV⁺ 687 n=17, squares: individuals born before 1980 receiving one dose of MVA-BN, triangles: individuals born 688 after 1980 receiving two doses of MVA-BN). Medians ± IQR are shown. The Mann-Whitney test was 689 used for comparisons.

690

691

692

693

694 695

696











В



13

Cyt. tot./CD8+

0.01-

1d (<1980)

° 0

0000

୷

ο

Unstim.

P = 0.0059

0

-8

о

Pan-PXV



MVA-BN



В





2d





0

MVA-HIVB

2d

P = 0.0020

ò

000

പ്പ

10

0.1

0.01

Cyt. tot./CD8+

Pie Figure Arc Legend Categories # IFN IL2 TNF IFN + 🛄 IL2 + + TNF + + + --+







Conv

Unstim.

P = 0.0313

o

Pan-PXV

С

Cyt. tot./CD8+

13

0.1-

0.01

Α



В







Α



MVA-121L

MVA-18L

MVA-121L

MVA-18L

TNF

MVA





В

MPXV

Pan-PXV





Α